Faust TW
Liver Study Unit, Section of Gastroenterology, Dept. of Internal Medicine, The University of Chicago Hospitals and Clinics, 5841 S. Maryland Ave., MC 4076, Chicago, IL 60637, USA.
Curr Treat Options Gastroenterol. 1999 Dec;2(6):491-504. doi: 10.1007/s11938-999-0053-y.
Many options are available to diagnose and treat patients with the Budd-Chiari syndrome who present with either thrombotic or non-thrombotic occlusion of the major hepatic veins and or vena cava. The goal of therapy is to alleviate venous obstruction and to preserve hepatic function. Low-sodium diets, diuretics, and therapeutic paracentesis are generally ineffective, except for the rare patient who presents with volume overload and incomplete hepatic venous occlusion. Anticoagulants and thrombolytics may be appropriate for selected patients with acute thrombotic venous obstruction. Percutaneous transluminal angioplasty (PTA) of hepatic venous stenoses or caval webs with or without placement of intraluminal stents yield excellent short-term results, but additional studies are warranted to assess long-term efficacy. Transjugular intrahepatic portosystemic shunts (TIPS) may be effective for patients with subacute or chronic disease and ascites refractory to sodium restriction and diuretics. Intrahepatic stents may also serve as a bridge to transplantation for selected patients presenting with fulminant hepatic failure consequent to hepatic venous occlusion. Additional studies will be necessary to assess the role of TIPS in the armamentarium of therapies for patients with the Budd-Chiari syndrome. Decompressive shunts, reconstruction of the vena cava and hepatic venous ostia, transatrial membranotomy, and dorsocranial resection of the liver with hepatoatrial anastomosis are appropriate options for patients with acute or subacute disease who are not candidates for, or fail less invasive therapies. The majority of patients benefit with improvement in liver function tests, ascites, and liver histology; however, hepatic function may deteriorate in patients with marginal reserve. Liver transplantation is reserved for patients with Budd-Chiari syndrome who present with fulminant hepatic failure or end-stage liver disease with portal hypertensive complications. Transplantation is also appropriate for patients who deteriorate after failed attempts at surgical shunting.
对于患有布加综合征的患者,有多种诊断和治疗方法可供选择,这些患者主要肝静脉和/或腔静脉存在血栓性或非血栓性阻塞。治疗的目标是缓解静脉阻塞并保护肝功能。低钠饮食、利尿剂和治疗性腹腔穿刺术通常无效,除非是极少数出现容量超负荷和不完全肝静脉阻塞的患者。抗凝剂和溶栓剂可能适用于某些急性血栓性静脉阻塞的患者。对肝静脉狭窄或腔静脉蹼进行经皮腔内血管成形术(PTA),无论是否放置腔内支架,都能取得出色的短期效果,但仍需进一步研究以评估长期疗效。经颈静脉肝内门体分流术(TIPS)对于患有亚急性或慢性疾病且腹水对限钠和利尿剂治疗无效的患者可能有效。肝内支架也可作为某些因肝静脉阻塞导致暴发性肝衰竭患者移植的桥梁。还需要进一步研究以评估TIPS在布加综合征患者治疗手段中的作用。减压分流术、腔静脉和肝静脉开口重建术、经心房膜切开术以及肝背侧切除术加肝心房吻合术,对于那些不适合或无法耐受侵入性较小治疗的急性或亚急性疾病患者来说是合适的选择。大多数患者的肝功能检查、腹水和肝脏组织学都会有所改善;然而,储备功能较差的患者肝功能可能会恶化。肝移植适用于患有暴发性肝衰竭或伴有门静脉高压并发症的终末期肝病的布加综合征患者。对于手术分流失败后病情恶化的患者,移植也是合适的选择。